Artículos por temáticas

Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies

Avila J, Pallas N, Bolós M, Sayas CL, Hernandez F.

Expert Opin Ther Targets. 2016 Jun;20(6):653-61. doi: 10.1517/14728222.2016.1131269. Epub 2016 Feb 16.

Promise of new Alzheimer's drug is dashed after lack of evidence

Hawkes N.

BMJ. 2016 Nov 24;355:i6362. doi: 10.1136/bmj.i6362.

Recent approaches and challenges in iPSCs: modeling and cell-based therapy of Alzheimer's disease

Csöbönyeiová M, Polák Š, Danišovič L.

Rev Neurosci. 2016 Jul 1;27(5):457-64. doi: 10.1515/revneuro-2015-0054.

Tannoid principles of Emblica officinalis renovate cognitive deficits and attenuate amyloid pathologies against aluminum chloride induced rat model of Alzheimer's disease

Justin Thenmozhi A, Dhivyabharathi M, William Raja TR, Manivasagam T, Essa MM.

Nutr Neurosci. 2016 Jul;19(6):269-78. doi: 10.1179/1476830515Y.0000000016. Epub 2015 Apr 4.

Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease

Choe YM, Kim KW, Jhoo JH, Ryu SH, Seo EH, Sohn BK, Byun MS, Bak JH, Lee JM, Yun HJ, Han MI, Woo JI, Lee DY.

Int J Geriatr Psychiatry. 2016 Jul;31(7):731-9. doi: 10.1002/gps.4384. Epub 2015 Nov 9.

Effects of Exercise on Functional Performance and Fall Rate in Subjects with Mild or Advanced Alzheimer's Disease: Secondary Analyses of a Randomized Controlled Study

Öhman H, Savikko N, Strandberg T, Kautiainen H, Raivio M, Laakkonen ML, Tilvis R, Pitkälä KH.

Dement Geriatr Cogn Disord. 2016;41(3-4):233-41. doi: 10.1159/000445712. Epub 2016 May 10.

Home-based caregiver training: Benefits differ by care receivers' dementia diagnosis

Kuo LM, Huang HL, Hsu WC, Wang YT, Shyu YL.

Geriatr Nurs. 2016 Sep-Oct;37(5):376-384. doi: 10.1016/j.gerinurse.2016.05.005. Epub 2016 Jun 10.

Potential therapeutic action of natural products from traditional Chinese medicine on Alzheimer's disease animal models targeting neurotrophic factors

Wei S.

Fundam Clin Pharmacol. 2016 Dec;30(6):490-501. doi: 10.1111/fcp.12222. Epub 2016 Aug 5.

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy

Sengupta U, Nilson AN, Kayed R.

EBioMedicine. 2016 Apr;6:42-49. doi: 10.1016/j.ebiom.2016.03.035. Epub 2016 Apr 5.

Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia

Owen RT.

Drugs Today (Barc). 2016 Apr;52(4):239-48. doi: 10.1358/dot.2016.52.4.2479357.

Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease

Rommer PS, Fuchs D, Leblhuber F, Schroth R, Greilberger M, Tafeit E, Greilberger J.

Neurodegener Dis. 2016;16(3-4):284-9. doi: 10.1159/000441565. Epub 2015 Nov 21.

Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease

Orhan IE, Senol FS.

Curr Top Med Chem. 2016;16(17):1889-96. doi: 10.2174/1568026616666160204121832.

Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease

Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E.

J Alzheimers Dis. 2016;49(4):1123-34. doi: 10.3233/JAD-150448.

[Preventive effects of curcumin and resveratrol in Alzheimer’s disease]

Tęcza P, Żylińska L.

Przegl Lek. 2016;73(5):320-3.

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Bra

Alzheimers Res Ther. 2016 May 12;8(1):18. doi: 10.1186/s13195-016-0189-7.